1
|
Charbe NB, Castillo F, Tambuwala MM, Prasher P, Chellappan DK, Carreño A, Satija S, Singh SK, Gulati M, Dua K, González-Aramundiz JV, Zacconi FC. A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers. Blood Rev 2022; 54:100927. [PMID: 35094845 DOI: 10.1016/j.blre.2022.100927] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Revised: 12/14/2021] [Accepted: 01/12/2022] [Indexed: 02/09/2023]
|
2
|
Shonaka T, Matsuno N, Obara H, Yoshikawa R, Nishikawa Y, Ishihara Y, Bochimoto H, Gochi M, Otani M, Kanazawa H, Azuma H, Sakai H, Furukawa H. Impact of human-derived hemoglobin based oxygen vesicles as a machine perfusion solution for liver donation after cardiac death in a pig model. PLoS One 2019; 14:e0226183. [PMID: 31825976 PMCID: PMC6905570 DOI: 10.1371/journal.pone.0226183] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Accepted: 11/21/2019] [Indexed: 12/21/2022] Open
Abstract
The recent clinical application of perfusion technology for the machine preservation of donation after cardiac death (DCD) grafts has some advantages. Oxygenation has been proposed for the preservation of DCD liver grafts. The aim of this study is to clarify whether the use of HbV-containing preservation solution during the subnormothermic machine perfusion (SNMP) of the liver graft improves the graft function of DCD porcine livers in an ex vivo reperfusion model. Pig livers were excised after 60 minutes of warm ischemic time and were preserved under one of three preservation conditions for 4 hours. The preservation conditions were as follows: 4°C cold storage (CS group; N = 5), Hypothermic machine preservation (HMP) with UW gluconate solution (HMP group; N = 5), SNMP (21°C) with UW gluconate solution (SNMP group; N = 5), SNMP (21°C) with HbVs (Hb; 1.8 mg/dl) perfusate (SNMP+HbV group; N = 5). Autologous blood perfusion was performed for 2 hours in an isolated liver reperfusion model (IRM). The oxygen consumption of the SNMP and SNMP+HbV group was higher than the HMP groups (p < 0.05). During the reperfusion, the AST level in the SNMP+HbV group was lower than that in the CS, HMP and SNMP groups. The changes in pH after reperfusion was significantly lower in SNMP+HbV group than CS and HMP groups. The ultrastructural findings indicated that the mitochondria of the SNMP+HbV group was well maintained in comparison to the CS, HMP and SNMP groups. The SNMP+HbVs preservation solution protected against metabolic acidosis and preserved the liver function after reperfusion injury in the DCD liver.
Collapse
Affiliation(s)
- Tatsuya Shonaka
- Department of Surgery, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| | - Naoto Matsuno
- Department of Surgery, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| | - Hiromichi Obara
- Department of Mechanical Engineering, Tokyo Metropolitan University, Hachioji-shi, Tokyo, Japan
| | - Ryo Yoshikawa
- Department of Mechanical Engineering, Tokyo Metropolitan University, Hachioji-shi, Tokyo, Japan
| | - Yuji Nishikawa
- Department of Pathology, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| | - Yo Ishihara
- Department of Surgery, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| | - Hiroki Bochimoto
- Department of Cell Physiology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan
| | - Mikako Gochi
- Department of Surgery, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| | - Masahide Otani
- Department of Surgery, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| | - Hiroyuki Kanazawa
- Department of Surgery, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| | - Hiroshi Azuma
- Department of Pediatrics, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| | - Hiromi Sakai
- Department of Chemistry, Nara Medical University, Kashihara-shi, Nara, Japan
| | - Hiroyuki Furukawa
- Department of Surgery, Asahikawa Medical University, Asahikawa-shi, Hokkaido, Japan
| |
Collapse
|
3
|
Estep TN. Pharmacokinetics and mechanisms of plasma removal of hemoglobin-based oxygen carriers. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2015; 43:203-15. [PMID: 26024447 DOI: 10.3109/21691401.2015.1047501] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The circulatory persistence, distribution, and metabolism of hemoglobin-based oxygen carriers (HBOCs) is a major determinant of their safety and efficacy. In this communication, published data on the pharmacokinetics and routes of plasma elimination of HBOCs are summarized and evaluated. The circulating half-life of HBOCs is dose-dependent in both animals and humans. Half-life also increases with molecular weight in animals, at least up to the MDa range. The functional half-life of HBOCs is diminished by as much as 40% due to oxidation of the heme group relative to the overall rate of removal of hemoglobin (Hb) from plasma. Kidney excretion of HBOCs is greatly diminished compared to that of unmodified Hb, but the liver remains a primary site of catabolism. Both hepatocytes and Kupffer cells have been implicated in receptor-mediated HBOC uptake. Removal also occurs in the spleen and/or bone marrow and probably at dispersed sites in the endothelium as well. HBOCs extravasate into the lymph at a rate inversely proportional to their molecular weight and are taken up by monocyte/macrophage CD163 receptors, both as free Hb and in complexes with haptoglobin (Hp). The interactions with both Hp and the CD163 receptor are altered by Hb modification. However, monocyte/macrophage uptake may not be a quantitatively important route for the removal of clinically relevant doses of HBOCs. The relative contributions of different removal pathways have yet to be comprehensively determined, particularly in humans.
Collapse
|
4
|
Fontes P, Lopez R, van der Plaats A, Vodovotz Y, Minervini M, Scott V, Soltys K, Shiva S, Paranjpe S, Sadowsky D, Barclay D, Zamora R, Stolz D, Demetris A, Michalopoulos G, Marsh JW. Liver preservation with machine perfusion and a newly developed cell-free oxygen carrier solution under subnormothermic conditions. Am J Transplant 2015; 15:381-94. [PMID: 25612645 PMCID: PMC5024042 DOI: 10.1111/ajt.12991] [Citation(s) in RCA: 97] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Revised: 07/28/2014] [Accepted: 08/23/2014] [Indexed: 01/25/2023]
Abstract
We describe a new preservation modality combining machine perfusion (MP) at subnormothermic conditions(21 °C) with a new hemoglobin-based oxygen carrier (HBOC) solution. MP (n=6) was compared to cold static preservation (CSP; n=6) in porcine orthotopic liver transplants after 9 h of cold ischemia and 5-day follow-up. Recipients' peripheral blood, serial liver biopsies, preservation solutions and bile specimens were collected before, during and after liver preservation. Clinical laboratorial and histological analyses were performed in addition to mitochondrial functional assays, transcriptomic, metabolomic and inflammatory inflammatory mediator analyses. Compared with CSP, MP animals had: (1) significantly higher survival (100%vs. 33%; p<0.05); (2) superior graft function (p<0.05);(3) eight times higher hepatic O2 delivery than O2 consumption (0.78 mL O2/g/h vs. 0.096 mL O2/g/h) during MP; and (4) significantly greater bile production (MP=378.5 ± 179.7; CS=151.6 ± 116.85). MP downregulated interferon (IFN)-α and IFN-γ in liver tissue. MP allografts cleared lactate, produced urea, sustained gluconeogenesis and produced hydrophilic bile after reperfusion. Enhanced oxygenation under subnormothermic conditions triggers regenerative and cell protective responses resulting in improved allograft function. MP at 21 °C with the HBOC solution significantly improves liver preservation compared to CSP.
Collapse
Affiliation(s)
- P. Fontes
- Department of SurgeryUniversity of Pittsburgh Medical CenterPittsburghPA,Department of SurgeryThomas E. Starzl Transplantation InstitutePittsburghPA,McGowan Institute of Regenerative MedicineUniversity of PittsburghPittsburghPA,Department of SurgeryUniversity of PittsburghPittsburghPA
| | - R. Lopez
- Department of SurgeryUniversity of Pittsburgh Medical CenterPittsburghPA,Department of SurgeryThomas E. Starzl Transplantation InstitutePittsburghPA
| | | | - Y. Vodovotz
- Department of SurgeryUniversity of PittsburghPittsburghPA
| | - M. Minervini
- Department of PathologyUniversity of Pittsburgh Medical CenterPittsburghPA
| | - V. Scott
- Department of AnesthesiaUniversity of PittsburghPittsburghPA
| | - K. Soltys
- Department of SurgeryUniversity of Pittsburgh Medical CenterPittsburghPA,Department of SurgeryThomas E. Starzl Transplantation InstitutePittsburghPA
| | - S. Shiva
- Vascular Medicine InstituteDepartment of Cardiothoracic SurgeryUniversity of PittsburghPittsburghPA
| | - S. Paranjpe
- Department of PathologyUniversity of PittsburghPittsburghPA
| | - D. Sadowsky
- Department of SurgeryUniversity of PittsburghPittsburghPA
| | - D. Barclay
- Department of SurgeryUniversity of PittsburghPittsburghPA
| | - R. Zamora
- Department of SurgeryUniversity of PittsburghPittsburghPA
| | - D. Stolz
- Department of PathologyUniversity of PittsburghPittsburghPA
| | - A. Demetris
- Department of PathologyUniversity of Pittsburgh Medical CenterPittsburghPA,Thomas E. Starzl Transplantation InstitutePittsburghPA
| | - G. Michalopoulos
- Department of PathologyUniversity of Pittsburgh Medical CenterPittsburghPA
| | - J. W. Marsh
- Department of SurgeryUniversity of Pittsburgh Medical CenterPittsburghPA,Department of SurgeryThomas E. Starzl Transplantation InstitutePittsburghPA
| |
Collapse
|
5
|
Abstract
After decades of research activities and product improvements in the field of artificial oxygen carriers based on either haemoglobin modifications or perfluorocarbon emulsions, these products have reached a critical stage of their development. Varieties of haemoglobin-based oxygen carriers and perfluorocarbon emulsions are under current clinical investigation. Although the clinical availability of artificial oxygen carriers may result in profound changes of fluid resuscitation from haemorrhage, the transfusion of human blood components as an integral part of medical trauma management will not be replaced. However, a rapid and effective restoration of tissue oxygenation by the use of artificial oxygen carriers in the treatment of severe haemorrhage may bridge time delays until stored and cross-matched human packed red cells are available. Whether artificial oxygen carriers could provide additional clinical benefits by sustaining tissue oxygenation even under conditions of a disturbed macro- or microcirculation is the subject of current investigations. Therefore, the application of safe and effective artificial oxygen carriers would not only be restricted to the treatment of severe haemorrhage, but additional therapeutic indications of artificial oxygen carriers in emergency medicine, trauma anaesthesia and other medical specialities would emerge.
Collapse
Affiliation(s)
- K F Waschke
- Department of Anaesthesiology and Critical Care Medicine, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany.
| | | |
Collapse
|
6
|
Jia Y, Buehler PW, Boykins RA, Venable RM, Alayash AI. Structural basis of peroxide-mediated changes in human hemoglobin: a novel oxidative pathway. J Biol Chem 2006; 282:4894-4907. [PMID: 17178725 DOI: 10.1074/jbc.m609955200] [Citation(s) in RCA: 119] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Hydrogen peroxide (H(2)O(2)) triggers a redox cycle between ferric and ferryl hemoglobin (Hb) leading to the formation of a transient protein radical and a covalent hemeprotein cross-link. Addition of H(2)O(2) to highly purified human hemoglobin (HbA(0)) induced structural changes that primarily resided within beta subunits followed by the internalization of the heme moiety within alpha subunits. These modifications were observed when an equal molar concentration of H(2)O(2) was added to HbA(0) yet became more abundant with greater concentrations of H(2)O(2). Mass spectrometric and amino acid analysis revealed for the first time that betaCys-93 and betaCys-112 were oxidized extensively and irreversibly to cysteic acid when HbA(0) was treated with H(2)O(2). Oxidation of further amino acids in HbA(0) exclusive to the beta-globin chain included modification of betaTrp-15 to oxyindolyl and kynureninyl products as well as betaMet-55 to methionine sulfoxide. These findings may therefore explain the premature collapse of the beta subunits as a result of the H(2)O(2) attack. Analysis of a tryptic digest of the main reversed phase-high pressure liquid chromatography fraction revealed two alpha-peptide fragments (alpha128-alpha139) and a heme moiety with the loss of iron, cross-linked between alphaSer-138 and the porphyrin ring. The novel oxidative pathway of HbA(0) modification detailed here may explain the diverse oxidative, toxic, and potentially immunogenic effects associated with the release of hemoglobin from red blood cells during hemolytic diseases and/or when cell-free Hb is used as a blood substitute.
Collapse
Affiliation(s)
- Yiping Jia
- Laboratory of Biochemistry and Vascular Biology, Division of Hematology, and the Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
| | - Paul W Buehler
- Laboratory of Biochemistry and Vascular Biology, Division of Hematology, and the Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
| | - Robert A Boykins
- Laboratory of Biophysics, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, and
| | - Richard M Venable
- Membrane Biophysics Section, Laboratory of Computational Biology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892
| | - Abdu I Alayash
- Laboratory of Biochemistry and Vascular Biology, Division of Hematology, and the Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892.
| |
Collapse
|
7
|
Schubert A, O'Hara JF, Przybelski RJ, Tetzlaff JE, Marks KE, Mascha E, Novick AC. Effect of diaspirin crosslinked hemoglobin (DCLHb HemAssist) during high blood loss surgery on selected indices of organ function. ARTIFICIAL CELLS, BLOOD SUBSTITUTES, AND IMMOBILIZATION BIOTECHNOLOGY 2002; 30:259-83. [PMID: 12227646 DOI: 10.1081/bio-120006118] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND The safety of the hemoglobin based oxygen carrier diaspirin crosslinked hemoglobin (DCLHb) has been reported only in the low (50-200 mg/kg) dose range [Przybelski. R.J.; Daily, E.K.; Kisicki, J.C.; Mattia-Goldberg, C.; Bounds, M.J.; Colburn, W.A. Phase I study of the safety and pharmacologic effects of diaspirin crosslinked hemoglobin solution. Crit. Care Med. 1996, 24 (12), 1993-2000, Bloomfield, E.; Rady, M.; Popovich, M.; Esfandiari, S.; Bedocs, N. The use of diaspirin crosslinked hemoglobin (DCLHb 1996, 95, (3A), A220.]. We conducted a randomized prospective open-label trial of DCLHb and packed red blood cells (PRBCs) in high-blood loss surgical patients to show the effect of 750 ml DCLHb (approximately 1000 mg/kg) on selected indices of organ function. METHOD After institutional approval, 24 patients scheduled to undergo elective orthopedic or abdominal surgery, were randomized to receive either PRBCs or 10% DCLHb within 12 hours after the start of surgery. Patients with renal insufficiency, abnormal liver function, severe coronary artery disease (CAD) and ASA physical status > or = IV were excluded. The anesthetic technique was left to the judgment of the anesthesiologist. Autologous predonation and intraoperative blood conservation techniques were utilized as appropriate. The indications for blood transfusion were individualized on disease state, stage of surgery, and plasma Hb concentration. Laboratory studies were obtained preoperatively and up to 28 days postoperatively. Patients were observed daily for development of jaundice, hematuria, nausea, vomiting, gastrointestinal discomfort, cardiac, respiratory, and infectious complications. Organ effects were assessed with urinalysis, creatinine clearance, electrocardiogram (ECG), and a panel of blood and serum laboratory tests. RESULTS The dose of DCLHb administered ranged from 680-1500 mg/kg (mean = 999 mg/kg). Estimated blood loss was 27 +/- 13 ml/kg and 31 +/- 15 ml/kg in the control and DCLHb groups, respectively. Fewer PRBCs (1.9 +/- 1.2 vs. 3.4 +/- 2.4 units. P = 0.06) were transfused to DCLHb patients on the operative day although this difference was no longer apparent later on. In the DCLHb group, 4/12 patients avoided any allogeneic PRBC transfusion vs. none in the control group (P = 0.09). Systolic, diastolic and mean blood pressure increased moderately after DCLHb for a period of 24-30 hours. There were no occurrences of cardiac ischemia. myocardial infarction, stroke, or pulmonary edema, by clinical or laboratory parameters up to the 28th postoperative day (POD). Seven of 12 (58%) DCLHb patients had yellow skin discoloration vs. none in the PRBC group (P < 0.01). Two of four non-urologic surgery patients developed asymptomatic postoperative hemoglobinuria after DCLHb. Creatinine clearance was unchanged postoperatively. Because of hemoglobin interference, bilirubin, gamma-glutamyl transferase (GGT), and amylase could not be measured reliably on POD1; on POD2. amylase was transiently elevated to 3 times ULN along with mild elevations of bilirubin, transaminases and BUN. Mean total creatine phoshokinase (CPK) peaked at 8 times the upper limit of normal (ULN) in the DCLHb group, compared with less than twice ULN for controls. Three DCLHb patients had prolonged ileus. Two of these patients had postoperative hyperamylasemia, one of whom developed mild pancreatitis. DCLHb did not affect white blood cell count or coagulation tests. CONCLUSION Administration of approximately 1000 mg/kg DCLHb was associated with transient arterial hypertension, gastrointestinal side effects, laboratory abnormalities, yellow skin discoloration, and hemoglobinuria. These observations point to opportunities for improvement in future synthetic hemoglobin design.
Collapse
Affiliation(s)
- Armin Schubert
- Department of General Anesthesiology, The Cleveland Clinic Foundation, OH 44195, USA.
| | | | | | | | | | | | | |
Collapse
|
8
|
Dougan T, Levy JB, Salama A, George AJT, Pusey CD. Characterization of autoantibodies from patients with Goodpasture's disease using a resonant mirror biosensor. Clin Exp Immunol 2002; 128:555-61. [PMID: 12067312 PMCID: PMC1906247 DOI: 10.1046/j.1365-2249.2002.01867.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Goodpasture's disease is characterized by the binding of IgG autoantibodies to the glomerular basement membrane, leading to glomerular inflammation. The autoantigen has been identified as the noncollagenous domain of the alpha3 chain of type IV collagen (alpha3(IV)NC1). We have used the IAsys resonant mirror biosensor to analyse the extent and affinity of binding of anti-GBM antibodies from sera of patients to purified alpha3(IV) NC1. alpha3(IV) NC1 monomers were immobilized to a carboxylate cuvette, with the simultaneous use of a control well. The binding of serum from patients with Goodpasture's disease (n = 12), normal controls (n = 14) and disease controls with vasculitis (n = 14) was analysed. Antibody binding was detected in sera from all patients with Goodpasture's disease but not from controls. IAsys measurements of binding correlated with antibody levels assessed by the standardized ELISA used for clinical assays. Both ELISA and biosensor measurements showed declining antibody levels in serial serum samples from treated patients; however, the biosensor detected antibody recrudescence when ELISA remained negative. Autoantibodies from patients' serum had average affinity constants (Kd) of 6.5 x 10-11M to 52.07 x 10-10M, as determined by an inhibition assay, indicating high affinity. Sips analysis showed that the antibody response was relatively homogeneous (values of 0.46-1). Biosensor techniques can therefore be used to detect and characterize anti-GBM antibodies in serum from patients, with high sensitivity and without need for antibody purification. This technique may be useful in diagnosis and monitoring of patients with Goodpasture's disease, and may be applicable to other autoantibody mediated diseases.
Collapse
Affiliation(s)
- T Dougan
- Renal Section and Department of Immunology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
| | | | | | | | | |
Collapse
|
9
|
Riess JG. Oxygen carriers ("blood substitutes")--raison d'etre, chemistry, and some physiology. Chem Rev 2001; 101:2797-920. [PMID: 11749396 DOI: 10.1021/cr970143c] [Citation(s) in RCA: 544] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- J G Riess
- MRI Institute, University of California at San Diego, San Diego, CA 92103, USA.
| |
Collapse
|
10
|
Affiliation(s)
- C P Stowell
- Blood Transfusion Service, Massachusetts General Hospital, Boston, Massachusetts, USA.
| | | | | | | |
Collapse
|
11
|
Friedman HI, Devenuto F, Kerwin A, Carson K, Bynoe R. Hemoglobin solutions as blood substitutes. J INVEST SURG 2000; 13:79-94. [PMID: 10801045 DOI: 10.1080/089419300272122] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Affiliation(s)
- H I Friedman
- Department of Surgery, University of South Carolina, School of Medicine, Columbia 29203, USA
| | | | | | | | | |
Collapse
|
12
|
Abstract
Artificial oxygen carriers may be grouped into modified hemoglobin solutions and fluorocarbon emulsions. In animal experiments, both have been shown to be efficacious in improving tissue oxygenation and as substitutes for blood transfusions. Advantages and disadvantages are being discussed in this article as well as the latest steps in the clinical development.
Collapse
Affiliation(s)
- D R Spahn
- Institut für Anästhesiologie, UniversitätsSpital, Zürich, Switzerland.
| |
Collapse
|
13
|
Abstract
The utilization of optical biosensors to study molecular interactions continues to expand. In 1998, 384 articles relating to the use of commercial biosensors were published in 130 different journals. While significant strides in new applications and methodology were made, a majority of the biosensor literature is of rather poor quality. Basic information about experimental conditions is often not presented and many publications fail to display the experimental data, bringing into question the credibility of the results. This review provides suggestions on how to collect, analyze and report biosensor data.
Collapse
Affiliation(s)
- D G Myszka
- University of Utah, Salt Lake City, UT 84132, USA.
| |
Collapse
|